2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
Snayd M, Leung V, Maloney M, Durante A, Macierowski B, Noel D, Muyombwe A, Razeq J, Banach D. 2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s714-s715. PMCID: PMC6253430, DOI: 10.1093/ofid/ofy210.2049.Peer-Reviewed Original ResearchState public health laboratoriesCRE isolatesNonsusceptible isolatesFosfomycin resistanceAntimicrobial Susceptibility Testing (EUCAST) criteriaCarbapenem-resistant Enterobacteriaceae infectionsOlder patient ageLimited treatment optionsResistance risk factorsSubstantial proportionEnterobacteriaceae clinical isolatesFosfomycin resistance ratePublic health laboratoriesLaboratory Standards InstituteSusceptibility testing criteriaCRE patientsPatient ageEnterobacteriaceae infectionsTreatment optionsRisk factorsResistance ratesWarrants evaluationCarbapenem resistanceBlaKPC geneCLSI criteria